Auditory function and quality of life in patients receiving cisplatin chemotherapy in head and neck cancer

Kalyanam, Balamurali; Sarala, N; Mohiyuddin, S. M. Azeem; Diwakar, Ravi B

doi:10.4103/0973-1482.188426

Cited by 13 publications

(6 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is common for there to be a reduction in QoL following the first three cycles of platinum-based chemotherapy in adults (Kalyanam et al 2018). Furthermore, it is well documented that hearing loss negatively impacts mental wellbeing and QoL, although the use of hearing aids appear to improve general QoL within the first year, emphasising the importance of early and proper diagnosistics (Hogan et al 2015;Fellinger et al 2007).…”

Section: Discussionmentioning

confidence: 99%

Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative synthesis systematic review

Pearson

Taylor

Patel

et al. 2019

International Journal of Audiology

View full text Add to dashboard Cite

Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative systematic review.Objective: To identify any change in quality of life (QoL) caused by chemotherapy-induced toxicities, such as hearing loss and tinnitus, to provide information in order to improve services and aid clinicians in their decisionmaking.Design: This systematic review followed the PRISMA checklist. The search terms were cancer, platinum-based chemotherapy, ototoxicity and "quality of life". Titles and abstracts, followed by full texts, were screened by two independent researchers. The relevant data were extracted and quality analysis was performed using the NIH Quality Assessment Tool.Study Sample: 308 titles and abstracts were screened, and 27 full text articles were screened. Ten articles representing 11 studies were included in the review.Study design included cross-sectional studies, randomised control trials and longitudinal studies.Results: Diagnostic criteria consisted of audiograms, questionnaires, and patient complaints. The study quality ranged from 21.43% to 85.71%. Overall results found that those treated with cisplatin had more hearing loss and tinnitus than those treated with other therapies. Furthermore, those with hearing loss and tinnitus were more likely to have a lower QoL.Conclusions: There is an urgent need to standardise diagnostics when investigating ototoxicity and its effect on QoL, particularly for research into risk factors, prevention and management.

show abstract

Section: Discussionmentioning

confidence: 99%

Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative synthesis systematic review

Pearson

Taylor

Patel

et al. 2019

International Journal of Audiology

View full text Add to dashboard Cite

show abstract

“…Ototoxicity is a side effect of cisplatin treatment characterized by bilateral, gradual, and severe hearing loss, with a prevalence of 40–80% in adult cancer patients and >50% in pediatric cancer patients 1. This ototoxicity can lead to a multifaceted decrease in the quality of life and notably impact the social and academic development of pediatric patients 2–4. Numerous protective compounds have been identified in preclinical studies and several are undergoing clinical trials 5,6.…”

Section: Introductionmentioning

confidence: 99%

<p>Dexamethasone-loaded injectable silk-polyethylene glycol hydrogel alleviates cisplatin-induced ototoxicity</p>

Chen

Liu

et al. 2019

IJN

View full text Add to dashboard Cite

Background: Cisplatin is an extensively used anti-neoplastic agent for the treatment of various solid tumors. However, a high incidence of severe ototoxicity is accompanied by its use in the clinic. Currently, no drugs or therapeutic strategies have been approved for the treatment of cisplatin-induced ototoxicity by the FDA. Purpose: The purpose of this study was to investigate the otoprotective effects of dexamethasone (DEX)-loaded silk-polyethylene hydrogel (DEX-SILK) following round window membrane administration in the cisplatin-induced ototoxicity mouse model. Methods: The morphology, gelation kinetics, viscosity and secondary structure of the DEX-SILK hydrogel were analyzed. DEX concentration in the perilymph was tested at different time points following hydrogel injection on the RWM niche. Cultured cells (HEI-OC1), organ of Corti explants (C57/BL6, P0-2), and cisplatin-induced hearing loss mice model (C57/BL6) were used as in vitro and in vivo models for investigating the otoprotective effects of DEX-SILK hydrogel against cisplatin. Results: Encapsulation of DEX with a loading of 8% (w/v) did not significantly change the silk gelation time, and DEX was evenly distributed in the Silk-PEG hydrogel as visualized by scanning electron microscopy (SEM). The concentration of Silk majorly influenced DEX distribution, morphological characteristics, viscosity, and gelation time. The optimized DEX-SILK hydrogel (8% w/v loading, 15% silk concentration, 10 μl) was administered directly onto the RWM of the guinea pigs. The DEX concentration in the perilymph was maintained above 1 μg/ml for at least 21 days for the DEX-SILK, while it was maintained for less than 6 h in the control sample of free DEX. DEX-SILK (5-60 ng/ml) exhibited significant protective effects against cisplatin-induced cellular ototoxicity and notably reduced the production of reactive oxygen species (ROS). Eventually, pretreatment with DEX-SILK effectively preserved outer hair cells in the cultured organ of Corti explants and demonstrated significant hearing protection at 4, 8, and 16 kHz in the cisplatin-induced hearing loss mice as compared to the effects noted following pretreatment with DEX. Conclusion: These results demonstrated the clinical value of DEX-SILK for the therapy of cisplatin-induced ototoxicity.

show abstract

“…Hearing loss can also contribute to difficulties in comprehension of health‐related communication and act as a barrier to supportive care and counseling of affected individuals 29 . Therefore, loss of hearing function, especially irreversible SNHL for which there is a lack of effective treatment, 29 can have long‐standing and devastating physical, functional, cognitive, social, emotional, and financial consequences along with the life of OPC survivors 30 …”

Section: Discussionmentioning

confidence: 99%

Association of hearing loss and tinnitus symptoms with health‐related quality of life among long‐term oropharyngeal cancer survivors

et al. 2022

View full text Add to dashboard Cite

Background This study investigated the association of hearing loss and tinnitus with overall health‐related quality of life (HRQoL) among long‐term oropharyngeal cancer (OPC) survivors. Methods This study included OPC survivors treated between 2000 and 2013 and surveyed from September 2015 to July 2016. Hearing loss and tinnitus were measured by asking survivors to rate their “difficulty with hearing loss and/or ringing in the ears” from 0 (not present) to 10 (as bad as you can imagine). Hearing loss and tinnitus scores were categorized as follows: 0 for none, 1–4 for mild, and 5–10 for moderate to severe. The primary outcome was the mean score of MD nderson Symptom Inventory Head & Neck module interference component as a HRQoL surrogate dichotomized as follows: 0 to 4 for none to mild and 5 to 10 for moderate to severe interference. Results Among 880 OPC survivors, 35.6% (314), reported none, 39.3% (347) reported mild, and 25.1% (221) reported moderate to severe hearing loss and tinnitus. On multivariable analysis, mild (OR, 5.83; 95% CI; 1.48–22.88; p = 0.012) and moderate (OR, 30.01; 95% CI; 7.96–113.10; p < 0.001) hearing loss and tinnitus were associated with higher odds of reporting moderate to severe symptom interference scores in comparison to no hearing loss and tinnitus. This association of hearing dysfunction was consistent with all domains of HRQoL. Conclusions Our findings provide preliminary evidence to support the need for continued audiological evaluations and surveillance to detect hearing dysfunction, to allow for early management and to alleviate the long‐term impact on QoL.

show abstract

Auditory function and quality of life in patients receiving cisplatin chemotherapy in head and neck cancer

Cited by 13 publications

References 13 publications

Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative synthesis systematic review

Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative synthesis systematic review

<p>Dexamethasone-loaded injectable silk-polyethylene glycol hydrogel alleviates cisplatin-induced ototoxicity</p>

Association of hearing loss and tinnitus symptoms with health‐related quality of life among long‐term oropharyngeal cancer survivors

Contact Info

Product

Resources

About